LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation.

    Villafuerte-Gutiérrez, Paola / López Rubio, Montserrat / Herrera, Pilar / Arranz, Eva

    Case reports in hematology

    2018  Volume 2018, Page(s) 5724960

    Abstract: Hematopoietic myeloproliferative neoplasms with FGFR1 rearrangement result in the 8p11 myeloproliferative syndrome that in the current Word Health Organization classification is designated as "myeloid and lymphoid neoplasm with FGFR1 abnormalities." We ... ...

    Abstract Hematopoietic myeloproliferative neoplasms with FGFR1 rearrangement result in the 8p11 myeloproliferative syndrome that in the current Word Health Organization classification is designated as "myeloid and lymphoid neoplasm with FGFR1 abnormalities." We report the case of a 66-year-old man who had clinical features that resembled chronic myeloid leukaemia (CML), but bone marrow cytogenetic and fluorescent in situ hybridization (FISH) studies showed t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. He was initially managed with hydroxyurea, and given the aggressive nature of this disease, four months later, the patient underwent an allogeneic hematopoietic stem-cell transplantation (HSCT) from an HLA-haploidentical relative. Currently, HSCT may be the only therapeutic option for long-term survival at least until more efficacious tyrosine kinase inhibitors (TKIs) become available.
    Language English
    Publishing date 2018-12-06
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2627639-2
    ISSN 2090-6579 ; 2090-6560
    ISSN (online) 2090-6579
    ISSN 2090-6560
    DOI 10.1155/2018/5724960
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Corrigendum to "Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update".

    Villafuerte-Gutierrez, Paola / Villalon, Lucia / Losa, Juan E / Henriquez-Camacho, Cesar

    Advances in hematology

    2019  Volume 2019, Page(s) 4120631

    Abstract: This corrects the article DOI: 10.1155/2014/986938.]. ...

    Abstract [This corrects the article DOI: 10.1155/2014/986938.].
    Language English
    Publishing date 2019-07-16
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2494501-8
    ISSN 1687-9112 ; 1687-9104
    ISSN (online) 1687-9112
    ISSN 1687-9104
    DOI 10.1155/2019/4120631
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Nontuberculous mycobacterial infection in a patient with myelofibrosis: case report and concise review.

    Henriquez-Camacho, Cesar / Martinez-Barranco, Pilar / Velasco, Maria / Villafuerte-Gutierrez, Paola / Losa, Juan

    Clinical case reports

    2015  Volume 3, Issue 6, Page(s) 438–441

    Abstract: A 70-year-old patient having massive refractory ascites in the course of idiopathic myelofibrosis was diagnosed of peritoneal extramedullary hematopoiesis and developed an overwhelming nontuberculous mycobacterial infection. The case describes this ... ...

    Abstract A 70-year-old patient having massive refractory ascites in the course of idiopathic myelofibrosis was diagnosed of peritoneal extramedullary hematopoiesis and developed an overwhelming nontuberculous mycobacterial infection. The case describes this unusual infection and highlights the need for additional studies to confirm the etiology of ascites in primary myelofibrosis.
    Language English
    Publishing date 2015-04-09
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.

    Villafuerte-Gutierrez, Paola / Villalon, Lucia / Losa, Juan E / Henriquez-Camacho, Cesar

    Advances in hematology

    2014  Volume 2014, Page(s) 986938

    Abstract: Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival. This paper reviews the guidelines ... ...

    Abstract Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival. This paper reviews the guidelines about febrile neutropenia in the setting of hematologic malignancies, providing an overview of the definition of fever and neutropenia, and categories of risk assessment, management of infections, and prophylaxis.
    Language English
    Publishing date 2014-11-27
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2494501-8
    ISSN 1687-9112 ; 1687-9104
    ISSN (online) 1687-9112
    ISSN 1687-9104
    DOI 10.1155/2014/986938
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies

    Paola Villafuerte-Gutierrez / Lucia Villalon / Juan E. Losa / Cesar Henriquez-Camacho

    Advances in Hematology , Vol

    A Critical Review and Update

    2014  Volume 2014

    Keywords Diseases of the blood and blood-forming organs ; RC633-647.5 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R
    Language English
    Publishing date 2014-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article: Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.

    Bastos-Oreiro, Mariana / Gutierrez, Antonio / Cabero, Almudena / López, Javier / Villafuerte, Paola / Jiménez-Ubieto, Ana / de Oña, Raquel / De la Fuente, Adolfo / Navarro, Belén / Peñalver, Javier / Martínez, Pilar / Alonso, Carmen / Infante, María / Córdoba, Raúl / Perez-Montero, Blanca / Pérez de Oteyza, Jaime / González de Villambrosio, Sonia / Fernández-Caldas, Paula / Del Campo, Raquel /
    García Belmonte, Daniel / Diaz-Gálvez, Javier / Salar, Antonio / Sancho, Juan-Manuel

    Cancers

    2024  Volume 16, Issue 7

    Abstract: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for ... ...

    Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for maintenance therapy notably improves outcomes; however, whether this can be achieved by using the same approach after R-B therapy is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens followed by rituximab maintenance therapy for untreated advanced-stage FL. The complete response rate at the end of induction was higher with R-B and relapses were more frequent with R-CHOP. During induction, cytopenias were significantly more frequent with R-CHOP and so was the use of colony-stimulating factors. During maintenance therapy, R-B showed more neutropenia and infectious toxicity. After a median follow-up of 81 months (95% CI: 77-86), the 6-year rates of progression-free survival (PFS) were 79% (95% CI: 72-86) for R-bendamustine vs. 67% (95% CI: 61-73) for R-CHOP (
    Language English
    Publishing date 2024-03-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16071285
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.

    Palanques-Pastor, Tomás / Megías-Vericat, Juan Eduardo / Martínez, Pilar / López Lorenzo, José Luis / Cornago Navascués, Javier / Rodriguez Macias, Gabriela / Cano, Isabel / Arnan Sangerman, Montserrat / Vidriales Vicente, María Belén / Algarra Algarra, Jesús Lorenzo / Foncillas, María Ángeles / Herrera, Pilar / Botella Prieto, Carmen / Vives, Susana / Figuera Álvarez, Ángela / Cuevas Palomares, Laida / Sobas, Marta / Contento Gonzalo, Alejandro / Cuello García, Rebeca /
    Amutio Diez, María Elena / De Miguel Llorente, Dunia / Navas Elorza, Begoña / Bergua Burgues, Juan Miguel / Bernal Del Castillo, Teresa / Mateos Rodríguez, María Carmen / de Cabo López, Erik / Franco Villegas, Ana Carolina / García Boyero, Raimundo / Escolano Escobar, Cristian / Seri Merino, Cristina / Cervero, Carlos / Roldán Pérez, Alicia / Hermosín Ramos, Lourdes / Cervera Calvo, Marta / Olave, María Telesa / Villafuerte Gutiérrez, Paola / de Laiglesiai, Almudena / Serrano, Josefina / Najera Irazu, María Josefa / Piñana, José Luis / Sanz, Miguel Ángel / Martínez-López, Joaquín / Montesinos, Pau

    Leukemia & lymphoma

    2021  Volume 62, Issue 12, Page(s) 2928–2938

    Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to ... ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
    MeSH term(s) Adult ; COVID-19 ; Humans ; Leukemia, Myeloid, Acute/epidemiology ; Leukemia, Myeloid, Acute/therapy ; Lopinavir ; Risk Factors ; SARS-CoV-2
    Chemical Substances Lopinavir (2494G1JF75)
    Language English
    Publishing date 2021-07-22
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1948031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top